• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24038 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2012     HAYES, Inc. Afirma® thyroid FNA analysis
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Positron emission tomography in combination with computed tomography (PET/CT) in minimal cognitive impairment and dementias]
2012     Penn Medicine Center for Evidence-based Practice (CEP) CT for acute chest pain
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Outpatient cardiac rehabilitation. part V: study protocol, multi-centre prospective controlled observational study with two parallel groups on outpatient cardiac phase III rehabilitation]
2012     HAYES, Inc. Anaplastic lymphoma kinase (ALK) gene rearrangement testing in non-small cell lung cancer (NSCLC)
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of pathologies accessible by transbronchial needle aspiration requiring anatomopathological diagnosis]
2012     Institute for Clinical Evaluative Sciences (ICES) Opening eyes, opening minds: the Ontario burden of mental illness and addictions report
2012     NIHR Health Technology Assessment programme A pragmatic randomised controlled trial to evaluate the cost-effectiveness of a physical activity intervention as a treatment for depression: the treating depression with physical activity (TREAD) trial
2012     Penn Medicine Center for Evidence-based Practice (CEP) Bone morphogenetic proteins and bone marrow aspirate concentrate for tibial fractures and long bone nonunions
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Occupational therapy. Part I: status quo in Austria and part II: occupational therapy for rheumatoid arthritis]
2012     HAYES, Inc. Fibrinogen-beta (FGB) c.-455G>A polymorphism testing in cardiovascular disease
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Photodynamic therapy for lung cancer]
2012     NIHR Health Technology Assessment programme Outcomes of social care for adults: developing a preference weighted measure
2012     Penn Medicine Center for Evidence-based Practice (CEP) Comparative effectiveness of devices for detection of respiratory distress in post-operative patients
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Occupational therapy part III. Occupational therapy for patients after stroke]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endometrial cell co-culture in patients receiving assisted reproduction treatments]
2012     Penn Medicine Center for Evidence-based Practice (CEP) Hyperthermic intraperitoneal chemotherapy
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Occupational therapy for dementia and depression]
2012     Andalusian Health Technology Assessment Area (AETSA) [Allomap genetic test for cardiac transplant rejection]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Biomedical treatment and diet supplements for the treatment of the autism spectrum disorder]
2012     HAYES, Inc. Cognitive-behavioral therapy for bulimia nervosa
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Extracorporeal shock wave therapy (ESWT) for the treatment of delayed union or non-union of fractures]
2012     HAYES, Inc. Harmony™ Prenatal Test
2012     Andalusian Health Technology Assessment Area (AETSA) [Heterochromatic flicker photometry for the detection of the risk of age-related macular degeneration]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endothelial cell count in subjects who underwent laser photorefractive surgery for myopia or keratoplasty for keratoconus]
2012     Penn Medicine Center for Evidence-based Practice (CEP) Electromagnetically-assisted feeding tube placement
2012     HAYES, Inc. Coronary artery calcium scoring to assess the risk of coronary artery disease in asymptomatic adults
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Bortezomib (Velcade®) as consolidation or maintenance therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma
2012     HAYES, Inc. Mammostrat® for prognosis of breast cancer recurrence
2012     Andalusian Health Technology Assessment Area (AETSA) [MicroRNAs as a diagnostic tool for lung cancer]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab for the treatment of chronic immune thrombocytopenic purpura]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Drug treatment of ADHD (Attention Deficit/Hyperactivity Disorder) in adults in Germany]
2012     NIHR Horizon Scanning Centre (NIHR HSC) Sebelipase alfa for lysosomal acid lipase deficiency
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2- negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole
2012     HAYES, Inc. Multiple endocrine neoplasia type 2 (MEN2)
2012     Andalusian Health Technology Assessment Area (AETSA) [Invasive telemonitoring in patients with heart failure]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Intravesical hyaluronic acid for painful bladder syndrome / interstitial cystitis]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Health technology assessment of a program for tertiary prevention of osteoporosis in patients with hip fracture]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical Practice Guideline on prevention and management of suicidal behaviour]
2012     HAYES, Inc. Custom total knee arthroplasty
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pertuzumab (Omnitarg/Perjeta®) for the first-line therapy of metastatic HER2 positive breast cancer
2012     HAYES, Inc. Thyroid hormone receptor beta (THRB) gene testing in resistance to thyroid hormone (RTH)
2012     Andalusian Health Technology Assessment Area (AETSA) [Digital tomosynthesis of the breast]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Catheter-directed mechanical thrombolysis in thromboembolic disease]
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rilpivirine (Edurant®)
2012     Andalusian Health Technology Assessment Area (AETSA) [Magnetic resonance guided focused ultrasound for uterine myomas ablation]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [eFlow® vibrating membrane nebulizer for the treatment of cystic fibrosis]
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rifaximin (Xifaxanta®)
2012     The Regional Health Technology Assessment Centre (HTA-centrum) [Medication reviews for patients in nursing homes. Part I: Effects on mortality and hospitalizations]
2012     Andalusian Health Technology Assessment Area (AETSA) [High-dose chemotherapy in the salvage treatment of metastatic germ cell tumours]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous tibial nerve stimulation for the treatment of overactive bladder]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Health technology assessment report on metal on metal hip resurfacing versus total hip replacement]
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Nevirapine (Viramune®)
2012     Health Information and Quality Authority (HIQA) Health technology assessment of a national deep brain stimulation service in Ireland
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Diagnostic agreement of digital whole slide imaging and routine light microscopy
2012     Andalusian Health Technology Assessment Area (AETSA) [Radiosurgery and stereotactic body radiation therapy. Efficacy, safety and efficiency in primary lung cancer and pulmonary oligometastases]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Sensor-augmented insulin pump for diabetic patients]
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Vitamin D supplementation in patients with active or latent tuberculosis
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease]
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Prosthetic arthroplasty in primary shoulder osteoarthritis
2012     Medical Advisory Secretariat (MAS) Specialized community-based care: an evidence-based analysis
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Biological tissue adhesive versus standard suture in conjuctival autograft for the surgical treatment of pterygium]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Federal structures of the prevention of alcohol misuse among children and youths]
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Intraoperative cortical stimulation in brain tumor surgery
2012     NIHR Health Technology Assessment programme Vemurafenib for the treatment of locally advanced or metastatic BRAF V600E mutation positive malignant melanoma
2012     The Regional Health Technology Assessment Centre (HTA-centrum) [Induction of labour at 41 completed until 42 completed gestational weeks, update of mini-HTA VGR 2007]
2012     NIHR Horizon Scanning Centre (NIHR HSC) Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) for mucopolysaccharidosis type IVA – first line
2012     The Regional Health Technology Assessment Centre (HTA-centrum) [Endovascular contra open surgical treatment of symptom generating atherosclerotic lesions of the external iliac artery]
2012     NIHR Horizon Scanning Centre (NIHR HSC) Fostamatinib for rheumatoid arthritis – second line
2012     Institute of Health Economics (IHE) First and second trimester prenatal screening for trisomies 13, 18, and 21 and open neural tube defects
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Timing of umbilical cord clamping for neonatal and maternal outcomes
2012     Andalusian Health Technology Assessment Area (AETSA) [Efficacy and safety of the immunoregulatory drugs interferon beta and glatiramer in the treatment of relapsing remitting multiple sclerosis]
2012     NIHR Horizon Scanning Centre (NIHR HSC) Thymosin beta-4 for dry eye syndrome
2012     Institute of Health Economics (IHE) Bariatric treatments for adult obesity
2012     The Regional Health Technology Assessment Centre (HTA-centrum) EEG as a diagnostic tool in patients with first episode psychosis
2012     Medical Advisory Secretariat (MAS) Genetic testing for predisposition to dilated cardiomyopathy
2012     NIHR Horizon Scanning Centre (NIHR HSC) Dexamethasone posterior segment drug delivery system (Ozurdex) for diabetic macular oedema– first or second line
2012     Institute of Health Economics (IHE) Insulin pump therapy for type 1 diabetes
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Psychological treatment of dental anxiety among adults
2012     Agenzia nazionale per i servizi sanitari regionali (Agenas) FDG-PET/CT for cancer staging
2012     NIHR Horizon Scanning Centre (NIHR HSC) Ciclosporin A (Cyclokat) for keratoconjunctivitis sicca
2012     NIHR Horizon Scanning Centre (NIHR HSC) Ponatinib for chronic myeloid leukaemia or Ph+ acute lymphoblastic leukaemia
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Botulinum toxin treatment of axillary and palmar hyperhidrosis
2012     Agenzia nazionale per i servizi sanitari regionali (Agenas) New devices for the management of glycaemia in young diabetics
2012     Medical Services Advisory Committee (MSAC) Pathology tests for latent mycobacterial infection
2012     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the implementation of clinical guidelines in the Basque Country. Cluster randomized trial]
2012     NIHR Horizon Scanning Centre (NIHR HSC) Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics
2012     NIHR Horizon Scanning Centre (NIHR HSC) Liposomal cisplatin (Nanoplatin) for advanced non-small cell lung cancer – first line
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Hyperbaric oxygen therapy in the treatment of diabetic foot ulcers and late radiation tissue injuries of the pelvis
2012     NIHR Horizon Scanning Centre (NIHR HSC) BI 201335 for chronic hepatitis C infection
2012     NIHR Horizon Scanning Centre (NIHR HSC) Liposomal cisplatin (Lipoplatin) in combination with gemcitabine for pancreatic cancer – first line
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Eculizumab treatment in paroxysmal nocturnal hemoglobinuria
2012     Medical Services Advisory Committee (MSAC) Testing for HER2 positivity in patients diagnosed with breast cancer to determine eligibility for treatment with trastuzumab
2012     NIHR Horizon Scanning Centre (NIHR HSC) Racecadotril for acute diarrhoea: infants (older than 3 months), children and adults – add on to oral rehydration therapy
2012     NIHR Horizon Scanning Centre (NIHR HSC) Enzalutamide for chemotherapy naive castration-resistant prostate cancer
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Reorientation of the Austrian parent-child preventive care programme. Part V: Preterm birth]
2012     NIHR Horizon Scanning Centre (NIHR HSC) Peginesatide for anaemia in chronic kidney disease – first and second line
2012     NIHR Horizon Scanning Centre (NIHR HSC) Trametinib in combination with dabrafenib for V600 BRAF positive advanced malignant melanoma – first line
2012     HAYES, Inc. Aquatic therapy for mobility impairment in children
2012     Medical Services Advisory Committee (MSAC) Testing for BRAF mutation in patients with metastatic melanoma for access to (1c) vemurafenib